$1.12
-0.04 (-3.45%)
Open$1.17
Previous Close$1.16
Day High$1.20
Day Low$1.09
52W High$2.59
52W Low$0.70
Volume—
Avg Volume519.8K
Market Cap50.18M
P/E Ratio—
EPS$-0.31
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+3,243.8% upside
Current
$1.12
$1.12
Target
$37.45
$37.45
$24.30
$37.45 avg
$44.03
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.42M | 3.79M | 3.81M |
| Net Income | -14,162,583 | 783.4K | 928.9K |
| Profit Margin | -994.5% | 20.7% | 24.4% |
| EBITDA | -15,860,660 | 1.80M | 1.92M |
| Free Cash Flow | — | 820.9K | 949.0K |
| Rev Growth | — | +6.9% | +13.5% |
| Debt/Equity | — | 0.92 | 0.74 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |